Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-23T23:31:34.029Z Has data issue: false hasContentIssue false

Effective doses of paliperidone palmitate (PAP): Retrospective analysis from three years of treatment

Published online by Cambridge University Press:  23 March 2020

S. Galiano Rus*
Affiliation:
Servicio Andaluz de Salud-UGC Jaén Norte, Unidad de Salud Mental Hospitalaria, Úbeda-Jaén, Spain
A. Soler Iborte
Affiliation:
Servicio Andaluz de Salud-UGC Jaén Norte, Unidad de Salud Mental Comunitaria, Linares-Jaén, Spain
C. Quesada González
Affiliation:
Servicio Andaluz de Salud-UGC Jaén, Unidad de Salud Mental Hospitalaria, Jaén, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The use of PAP is already much extended in general. The recommended doses in the technical specifications of the drugs, as the result of trial studies, differ from the doses administered in habitual clinical practice. Therefore, the justification of this study is to monitor the average doses prescribed, to be able to reach an agreement on the best doses. To retrospectively analyze the first 32 patients in our area of healthcare, who were prescribed PAP, the doses used at the start of treatment and after 3 years.

Materials and methods

Two initial doses of PAP were analyzed, maximum and current (outpatient) in 32 patients attended in the area of mental health of North Jaen, who started the treatment with PAP between 2012 and 2013, with an average length of time of 2.55 years (SD 2.02). We evaluated the diagnosis (schizophrenia and related disorders, ICD-10 F20), the number of hospital admissions previous and posterior to the start of the treatment and change in weight.

Results

Average doses: initial: 110.15 mg (SD 32.83), maximum: 165.51 mg (SD 29.76) and maintenance: 146.81 mg (SD 29.59). Average hospital admissions: prior and posterior to the start of treatment: 1.5 and 0.83. An average reduction of 44.06% in admissions was observed.

Conclusions

The data obtained suggests that a dose of 75–200 mg could be effective in the maintenance of patients with schizophrenia and for decreasing the number of new hospital admissions. Fifty percent of the cases can be compensated with long acting peliperidone as a monotherapy.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV1011
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.